ASMB at a glance
Assembly Biosciences Inc (ASMB, SEC CIK 1426800) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 14, 2026 and Form 4 insider filings as recently as June 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Assembly Biosciences Inc (ASMB) shares worth $213.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bjorkquist Jeanette M on June 17, 2026 of 29 shares at $23.25 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $72.3M
- +153.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $213.8M · +4 vs prior quarter
- Latest 10-Q
- Aug 13, 2026
- Quarterly report
SignalX for ASMB
Don't miss the next ASMB filing
- Alerts as it files. A push when ASMB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASMB, by share count.
- Ask anything. An AI agent that reads every ASMB filing and answers with sources.
ASMB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bjorkquist Jeanette M | Sell | Jun 17, 2026 | 29 | $23.25 |
| Bjorkquist Jeanette M | Sell | Jun 17, 2026 | 29 | $23.25 |
| Houghton Michael | A | Jun 4, 2026 | 8,000 | - |
| Johnson-Pratt Lisa | A | Jun 4, 2026 | 8,000 | - |
| ALTIG ANTHONY E | A | Jun 4, 2026 | 8,000 | - |
| Consylman Gina | A | Jun 4, 2026 | 8,000 | - |
| McHutchison John G | A | Jun 4, 2026 | 8,000 | - |
| Mahony Susan | A | Jun 4, 2026 | 8,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $28.5M | $72.3M |
| Operating Income | - | -$45.4M | -$12.1M |
| Net Income | -$61.2M | -$40.2M | -$6.1M |
| Op. Margin | - | -159.3% | -16.8% |
| Net Margin | - | -140.9% | -8.5% |
| Balance Sheet | |||
| Total Assets | $136.8M | $119.2M | $257.6M |
| Equity | - | $33.4M | $206.8M |
| ROE | - | -120.4% | -3.0% |
| Per Share | |||
| EPS | $-13.38 | $-6.69 | $-0.55 |
| Cash Flow | |||
| Operating CF | - | -$51.1M | -$41.1M |
| CapEx | $255K | $28K | $66K |
Source: XBRL data in Assembly Biosciences Inc (ASMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ASMB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $213.8M |
| Q1 2026 | 18 | $167.7M |
| Q4 2025 | 16 | $202.4M |
| Q3 2025 | 15 | $164.1M |
| Q2 2025 | 12 | $49.7M |
| Q1 2025 | 11 | $24.9M |
| Q4 2024 | 6 | $40.5M |
| Q3 2024 | 5 | $2.4M |
- BlackRock+564.1K (+278%)
- Gilead Sciences+471.7K (+10%)
- State Street Corp+115.2K (+203%)
- Goldman Sachs Group+101.6K (+281%)
- Northern Trust+82.0K (+200%)
- JPMorgan Chase & Co−7.6K (-14%)
- Two Sigma Investments−2.7K (-13%)
- Citigroup−1.9K (-30%)
- Bank of America Corp−1.3K (-12%)
- Ameriprise Financial+230.0K
- Franklin Resources+113.2K
- BNY Mellon+24.0K
- Invesco Ltd+11.9K
- Wells Fargo & Co+8.3K
- Blackstone Group−296.9K
- U.S. Bancorp−59
- Fifth Third Bancorp−57
Source: 13F-HR filings on SEC EDGAR (aggregated from 105 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASMB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ASMB SEC filings: frequently asked questions
Which institutions hold ASMB stock?
As of June 30, 2026, the largest Assembly Biosciences Inc (ASMB) holders among the 13F filers tracked by SignalX were Gilead Sciences ($136.8 million), BlackRock ($21.1 million), Vanguard Capital Management LLC ($15.4 million), Millennium Management ($8.2 million), Ameriprise Financial ($6.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASMB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55. The figures come from the XBRL data in the 10-K.
What are the latest ASMB SEC filings?
Assembly Biosciences Inc (ASMB) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 14, 2026 and a Form 4 insider filing on June 18, 2026.
What is ASMB's SEC CIK number?
Assembly Biosciences Inc (ASMB)'s SEC Central Index Key (CIK) is 1426800. EDGAR lists every ASMB filing under that number.
Ask anything about ASMB
The research agent reads ASMB's filings, financials, insider trades and 13F holders, then answers with sources.